PT-141 (bremelanotide): how melanocortin signaling affects desire
A look at the central nervous system pathway behind bremelanotide — and what the FDA approval for Vyleesi actually means.
TL;DR
- PT-141 (bremelanotide) is an MC4R agonist — it acts on melanocortin receptors in the hypothalamus, not on the vascular system like most prior sexual dysfunction drugs.
- Bremelanotide is the active ingredient in Vyleesi, which the FDA approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Compounded versions of bremelanotide are distinct from the FDA-approved branded product and are not themselves FDA-approved.
What it is
PT-141, generically called bremelanotide, is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It is the active pharmaceutical ingredient in Vyleesi, a subcutaneous autoinjector that the FDA approved in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by low sexual desire that is not attributable to a co-occurring condition or medication and that causes personal distress. The FDA approval applies to the branded Vyleesi product at the studied dose and formulation.
How it works
Most medications used for sexual dysfunction act peripherally — on blood vessels, smooth muscle, or local tissue. PT-141 works differently. It is a melanocortin receptor agonist, with particular affinity for the MC4R subtype, which is expressed in the hypothalamus and other central nervous system regions involved in sexual arousal and motivation.
The working model, supported by the clinical trial data underlying the Vyleesi approval, is that MC4R activation in hypothalamic circuits modulates dopaminergic pathways associated with desire and motivation — a central mechanism rather than a peripheral vascular one. This is relevant because it suggests a different use case than PDE5 inhibitors, which act on vascular smooth muscle: PT-141 addresses the desire and motivation component, not the mechanical response.
Subcutaneous injection is the approved route. Onset of action is approximately 45 minutes, with effects lasting several hours. The FDA label notes that it should not be used more than once in 24 hours or more than eight times per month.
Who asks about it
PT-141 draws interest from two overlapping groups: premenopausal women who have been diagnosed with or suspect HSDD and want to understand their options, and individuals who have heard about PT-141 in broader performance contexts and want to understand what the compound actually is and what the evidence supports. The Vyleesi approval is specific to premenopausal women with HSDD; use in other contexts is outside the approved indication.
What the research says
The FDA approval was based on two Phase III randomized, placebo-controlled trials submitted to the agency. In the pivotal trials, women using bremelanotide reported statistically significant improvements in desire and decreases in distress compared to placebo. The FDA label (2019) notes common adverse events including nausea (40%), flushing, and injection-site reactions. Transient blood pressure increases have been observed; the label includes a contraindication for patients with cardiovascular disease.
The published literature on PT-141 in male HSDD and other populations is limited and primarily from earlier Phase II studies. The compound has been studied in the context of male erectile dysfunction in Phase II trials, but the FDA has not approved bremelanotide for use in men.
What to know before considering it
Vyleesi (bremelanotide) is an FDA-approved prescription drug. Compounded bremelanotide — where a licensed 503A compounding pharmacy prepares the compound from active pharmaceutical ingredient — is not the same as the approved product and is not itself FDA-approved. Any access to bremelanotide, whether branded or compounded, requires a valid prescription from a licensed clinician who has conducted an appropriate evaluation. Nausea is the most commonly reported adverse event; the cardiovascular contraindication is clinically significant. This is a post-physician-evaluation conversation, not a self-directed purchase.
The Halftime POV
Bremelanotide is one of the few peptide-derived compounds to complete the full FDA approval pathway and land on the market as a branded drug. That matters. It means the mechanism has been tested in rigorous controlled trials and the benefit-risk profile has been reviewed. The compounded version is not equivalent to the approved drug — a distinction we take seriously. If PT-141 is relevant to your clinical picture, the starting point is an honest evaluation, not a shortcut.
Related reading:
FAQ
Q: What is PT-141? A: PT-141 (bremelanotide) is a melanocortin receptor agonist — specifically, it acts on MC3R and MC4R receptors in the central nervous system. The FDA-approved branded version (Vyleesi) is indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women. Compounded versions use the same active ingredient but are not FDA-approved products.
Q: How does PT-141 work? A: Unlike phosphodiesterase-5 inhibitors (such as sildenafil), PT-141 does not work primarily through vascular mechanisms. It activates melanocortin receptors in the hypothalamus and limbic system, which are involved in central regulation of sexual arousal. The central mechanism is why it may be effective in cases where vascular-acting compounds are not.
Q: Is PT-141 FDA-approved? A: Bremelanotide is FDA-approved as Vyleesi for HSDD in premenopausal women. Compounded versions of the active ingredient are not FDA-approved but may be legally dispensed through 503A compounding pharmacies with a valid prescription. Access requires a clinician evaluation.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- FDA Prescribing Information: Vyleesi (bremelanotide injection), 2019
- Simon JA, et al. “Efficacy and safety of bremelanotide for hypoactive sexual desire disorder.” Obstetrics & Gynecology, 2019
- Pfaus JG, et al. “The melanocortin system and female sexual behavior.” Hormones and Behavior, 2007
